Journal Article > Research

Culture conversion at 6 months in patients receiving delamanid-containing regimens for the treatment of multidrug-resistant tuberculosis

Abstract

Delamanid should be effective against highly resistant strains of Mycobacteriumtuberculosis, but uptake has been slow globally. In the endTB (expand new drug markets for TB) Observational Study, which enrolled a large, heterogeneous cohorts of patients receiving delamanid as part of a multidrug regimen, 80% of participants experienced sputum culture conversion within 6 months.

Subject Area
Published Date
11-Jul-2020
PubMed ID
31676905
Languages
English
Volume / Issue / Pages
Volume 71, Issue 2, Pages 415-418
Dimensions Badge